365 related articles for article (PubMed ID: 27333051)
1. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.
Benamar M; Guessous F; Du K; Corbett P; Obeid J; Gioeli D; Slingluff CL; Abbas T
EBioMedicine; 2016 Aug; 10():85-100. PubMed ID: 27333051
[TBL] [Abstract][Full Text] [Related]
2. The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors.
Vanderdys V; Allak A; Guessous F; Benamar M; Read PW; Jameson MJ; Abbas T
Mol Cancer Ther; 2018 Feb; 17(2):368-380. PubMed ID: 28838998
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer.
Pan WW; Zhou JJ; Yu C; Xu Y; Guo LJ; Zhang HY; Zhou D; Song FZ; Fan HY
J Biol Chem; 2013 Oct; 288(41):29680-91. PubMed ID: 23995842
[TBL] [Abstract][Full Text] [Related]
4. Selective ubiquitylation of p21 and Cdt1 by UBCH8 and UBE2G ubiquitin-conjugating enzymes via the CRL4Cdt2 ubiquitin ligase complex.
Shibata E; Abbas T; Huang X; Wohlschlegel JA; Dutta A
Mol Cell Biol; 2011 Aug; 31(15):3136-45. PubMed ID: 21628527
[TBL] [Abstract][Full Text] [Related]
5. CDK1-dependent inhibition of the E3 ubiquitin ligase CRL4CDT2 ensures robust transition from S Phase to Mitosis.
Rizzardi LF; Coleman KE; Varma D; Matson JP; Oh S; Cook JG
J Biol Chem; 2015 Jan; 290(1):556-67. PubMed ID: 25411249
[TBL] [Abstract][Full Text] [Related]
6. Regulation of TGF-β signaling, exit from the cell cycle, and cellular migration through cullin cross-regulation: SCF-FBXO11 turns off CRL4-Cdt2.
Abbas T; Keaton M; Dutta A
Cell Cycle; 2013 Jul; 12(14):2175-82. PubMed ID: 23892434
[TBL] [Abstract][Full Text] [Related]
7. CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-Set7/Set8-mediated cellular migration.
Abbas T; Mueller AC; Shibata E; Keaton M; Rossi M; Dutta A
Mol Cell; 2013 Mar; 49(6):1147-58. PubMed ID: 23478445
[TBL] [Abstract][Full Text] [Related]
8. CRL4(Cdt2)-mediated destruction of the histone methyltransferase Set8 prevents premature chromatin compaction in S phase.
Centore RC; Havens CG; Manning AL; Li JM; Flynn RL; Tse A; Jin J; Dyson NJ; Walter JC; Zou L
Mol Cell; 2010 Oct; 40(1):22-33. PubMed ID: 20932472
[TBL] [Abstract][Full Text] [Related]
9. CRL4(Cdt2) regulates cell proliferation and histone gene expression by targeting PR-Set7/Set8 for degradation.
Abbas T; Shibata E; Park J; Jha S; Karnani N; Dutta A
Mol Cell; 2010 Oct; 40(1):9-21. PubMed ID: 20932471
[TBL] [Abstract][Full Text] [Related]
10. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
[TBL] [Abstract][Full Text] [Related]
11. CRL4(CDT2) targets CHK1 for PCNA-independent destruction.
Huh J; Piwnica-Worms H
Mol Cell Biol; 2013 Jan; 33(2):213-26. PubMed ID: 23109433
[TBL] [Abstract][Full Text] [Related]
12. The CRL4Cdt2 ubiquitin ligase targets the degradation of p21Cip1 to control replication licensing.
Kim Y; Starostina NG; Kipreos ET
Genes Dev; 2008 Sep; 22(18):2507-19. PubMed ID: 18794348
[TBL] [Abstract][Full Text] [Related]
13. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells.
Lin JJ; Milhollen MA; Smith PG; Narayanan U; Dutta A
Cancer Res; 2010 Dec; 70(24):10310-20. PubMed ID: 21159650
[TBL] [Abstract][Full Text] [Related]
14. C/EBPα regulates CRL4(Cdt2)-mediated degradation of p21 in response to UVB-induced DNA damage to control the G1/S checkpoint.
Hall JR; Bereman MS; Nepomuceno AI; Thompson EA; Muddiman DC; Smart RC
Cell Cycle; 2014; 13(22):3602-10. PubMed ID: 25483090
[TBL] [Abstract][Full Text] [Related]
15. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression.
Jia L; Li H; Sun Y
Neoplasia; 2011 Jun; 13(6):561-9. PubMed ID: 21677879
[TBL] [Abstract][Full Text] [Related]
16. PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex.
Abbas T; Sivaprasad U; Terai K; Amador V; Pagano M; Dutta A
Genes Dev; 2008 Sep; 22(18):2496-506. PubMed ID: 18794347
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of CRL4(Cdt2), a PCNA-dependent E3 ubiquitin ligase.
Havens CG; Walter JC
Genes Dev; 2011 Aug; 25(15):1568-82. PubMed ID: 21828267
[TBL] [Abstract][Full Text] [Related]
18. SET8 is degraded via PCNA-coupled CRL4(CDT2) ubiquitylation in S phase and after UV irradiation.
Jørgensen S; Eskildsen M; Fugger K; Hansen L; Larsen MS; Kousholt AN; Syljuåsen RG; Trelle MB; Jensen ON; Helin K; Sørensen CS
J Cell Biol; 2011 Jan; 192(1):43-54. PubMed ID: 21220508
[TBL] [Abstract][Full Text] [Related]
19. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.
Blank JL; Liu XJ; Cosmopoulos K; Bouck DC; Garcia K; Bernard H; Tayber O; Hather G; Liu R; Narayanan U; Milhollen MA; Lightcap ES
Cancer Res; 2013 Jan; 73(1):225-34. PubMed ID: 23100467
[TBL] [Abstract][Full Text] [Related]
20. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
